Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Health Minister Shiozaki Retains Post in Cabinet Reshuffle
August 4, 2016
- MHLW Issues Alert on Teratogenic Risk of CellCept, Generic Versions: Safety Bulletin
August 3, 2016
- MHLW to Gauge Possible Deregulation of Plasma Export Restriction towards FY2018: Blood Division Chief
August 3, 2016
- MHLW Study Underway to Delineate Scope of “Essential Drugs”: Official
August 2, 2016
- Japan Should Reward Innovative Startups through Drug Prices: Report
August 2, 2016
- MHLW Releases Interim Report for Full-Fledged Rollout of MID-NET
August 1, 2016
- Compassionate Use Scheme Applied to Pfizer’s Crizotinib
August 1, 2016
- MHLW Alerts on αβ T-Cell Therapy after Opdivo
July 29, 2016
- MHLW Official Positive about Seeking Budgets to Boost PMDA Reviewers
July 29, 2016
- Pricy Meds Issue Takes a Step Forward with 2-Faceted Proposal
July 29, 2016
- Chuikyo OKs Plan to Compile “Optimal Use Guidelines,” Beginning with Opdivo, Repatha
July 28, 2016
- Chuikyo to Discuss Out-of-Cycle Re-Pricing for Opdivo, but JMA Turns Wary
July 28, 2016
- MHLW to Work with PMDA from an Early Stage to Build Clinical Innovation Network: Division Head
July 28, 2016
- MHLW to Canvass Drug Makers’ Opinions on Real-World Roles of “3 Key Officers”: Pharma Safety Head
July 27, 2016
- Expert Taskforce Roughly OKs Report on Genomic Medicine
July 26, 2016
- ICH Clinical Trial Guidelines Allow Flexibility on Number of Japanese Subjects Needed: PMDA Official
July 26, 2016
- Revised GCP Ordinances Open Ways for Compassionate Use of Medical Devices, Regenerative Medicines
July 25, 2016
- MHLW Panel to Review ASKA’s Hepatic Encephalopathy Drug, Opdivo’s RCC Indication on Aug. 5
July 25, 2016
- Intractable Neurological, Psychiatric Diseases Initially Eyed for PMDA-NCNP Drug Development Guidelines
July 25, 2016
- MHLW Alerts on Use of EGFR TKIs in Opdivo-Treated Patients after 3 Deaths
July 25, 2016
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…